$IDRA (Idera Pharmaceuticals, Inc.)

$IDRA {{ '2015-08-07T18:31:11+0000' | timeago}} • Announcement

$IDRA announced that Louis Arcudi, CFO, will present a corporate update at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 11, 2015 at 3:05 p.m. Eastern Time at the Le Parker Meridien Hotel in New York City.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$BIIB {{ '2017-09-12T12:31:48+0000' | timeago}} • Announcement

$BIIB named Sanjay Jariwala as SVP, Worldwide Medical. Jariwala will be responsible for leading and driving $BIIB's Worldwide Medical strategy working closely with the company’s global therapeutic operations and R&D leadership teams. He will be based in Cambridge, Massachusetts, and report directly to Chief Medical Officer Alfred Sandrock, Jr.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$ABBV {{ '2017-09-08T16:14:15+0000' | timeago}} • Announcement

$ABBV's BoD declared a quarterly cash dividend of $0.64 per share. The dividend is payable on Nov. 15, 2017 to stockholders of record on Oct. 13, 2017. Since the company's inception in 2013, $ABBV has increased its dividend by 60%.

$INCY {{ '2017-09-08T12:59:10+0000' | timeago}} • Announcement

$INCY priced its underwritten public offering of 4.945MM shares of its common stock. The company has granted the underwriter an option to purchase up to an additional 741,750 shares of common stock. The offering is expected to close on Sept. 12, 2017.

$BMY {{ '2017-09-07T13:34:21+0000' | timeago}} • Announcement

$BMY said a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary endpoint. This demonstrates superior overall survival (OS) compared to sunitinib in intermediate- and poor-risk patients.

$ABBV {{ '2017-09-06T15:45:07+0000' | timeago}} • Announcement

$ABBV, in cooperation with $NBIX, has submitted a New Drug Application to the FDA for elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, being evaluated for the management of endometriosis with associated pain. The pain includes daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse.

$INCY {{ '2017-08-31T12:36:56+0000' | timeago}} • Announcement

$INCY said a study conducted by the European Society for Medical Oncology revealed that epacadostat, the company’s selective IDO1 enzyme inhibitor, demonstrated strong and durable responses in patients with advanced melanoma, when administrated in combination with KEYTRUDA. The society is expected to release the detailed results next month.

$LLY {{ '2017-08-30T13:53:36+0000' | timeago}} • Announcement

$LLY to resubmit the New Drug Application for rheumatoid arthritis medication Baricitinib, to the U.S. FDA, before the end of January 2018. Last month, Lilly and its development and marketing partner $INCY announced that resubmission of Baricitinib will take at least 18 months.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$ENDP {{ '2017-08-28T11:57:14+0000' | timeago}} • Announcement

Pharma company $ENDP said its operating subsidiary Par Pharmaceutical has received final approval from the FDA for 'vigabatrin oral solution.' The company has started shipping of the medicine. The medicine, which is the generic version of Sabril, is the first and only generic version available.

$LRCX {{ '2017-08-09T14:16:49+0000' | timeago}} • Announcement

$LRCX and $NSTG announced a strategic collaboration to develop $NSTG’s proprietary Hyb & Seq next-generation sequencing platform. $LRCX will provide up to $50MM of funding over a development period expected to last about 3 years. $LRCX will also receive a warrant to purchase 1MM shares of $NSTG common stock at $16.75 per share.

$VRX {{ '2017-08-08T18:56:32+0000' | timeago}} • Webcast

$VRX cuts FY17 revenue guidance by $200MM to about $8.70-8.90Bil. This reflects the loss of approx. $170MM of Dendreon revenues. The overall reduced outlooks is mostly due to the revised expectation of the struggling Dermatology business.

$VRX {{ '2017-08-08T18:56:03+0000' | timeago}} • Webcast

During 2Q17, $VRX announced the use of cash on hand to redeem $500MM of outstanding senior notes due 2018. Since 1Q16, the company reduced total debt to $4.8Bil. $VRX expects to exceed the commitment of paying down $5Bil of debt from divestiture proceeds and free cash flow before February 2018.

$VRX {{ '2017-08-08T18:54:54+0000' | timeago}} • Webcast

$VRX's dermatology business continues to underperform. To address the challenges, the company has stabilized Derm ASP and have rebranded the business unit as Ortho Dermatologics during 2Q17. The company launched SILIQ on July. 27, 2017 as the new product under this business unit.

$VRX {{ '2017-08-08T14:16:40+0000' | timeago}} • Announcement

For FY17, $VRX lowered its revenue to about $8.70-8.90Bil from $8.90-9.10Bil. The company also plans to exceed commitment to pay down $5Bil in debt from divestiture proceeds and free cash flow before February 2018.

$VRX {{ '2017-08-08T14:07:13+0000' | timeago}} • Announcement

$VRX, Quebec-based drugmaker, reported 8% drop in its 2Q17 revenue to $2.23Bil. This decrease was mainly due to decline in volume and pricing of its U.S. Diversified Products segment. The company's net loss narrowed to $38MM, or $0.11 per share, compared to $302MM or $0.88 per share during 2Q16, mostly due to progress in debt reduction.

$VRX {{ '2017-08-08T12:03:05+0000' | timeago}} • Infographic

$VRX Valeant Pharmaceuticals International Earnings AlphaGraphics: Q2 2017 highlights

Recent Transcripts

NSTG (NanoString Technologies, Inc.)
Tuesday, August 8 2017 - 8:30pm
HALO (Halozyme Therapeutics, Inc.)
Tuesday, August 8 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
BCRX (BioCryst Pharmaceuticals, Inc.)
Monday, August 7 2017 - 3:00pm
CMRX (Chimerix, Inc.)
Monday, August 7 2017 - 12:30pm
NBIX (Neurocrine Biosciences Inc.)
Thursday, August 3 2017 - 9:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
MNTA (Momenta Pharmaceuticals Inc.)
Wednesday, August 2 2017 - 2:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
HSKA (Heska Corporation)
Monday, July 31 2017 - 3:00pm
QGEN (Qiagen NV)
Friday, July 28 2017 - 1:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
KERX (Keryx Biopharmaceuticals Inc.)
Thursday, July 27 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
NBIX (Neurocrine Biosciences Inc.)
Tuesday, May 9 2017 - 9:00pm
HALO (Halozyme Therapeutics, Inc.)
Tuesday, May 9 2017 - 8:30pm
CMRX (Chimerix, Inc.)
Tuesday, May 9 2017 - 12:30pm

AlphaGraphics you may like